These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39244216)

  • 1. Intratumoral CXCL13
    Wang J; Liang Y; Xue A; Xiao J; Zhao X; Cao S; Li P; Dong J; Li Y; Xu Z; Yang L
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
    Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.
    Yamakoshi Y; Tanaka H; Sakimura C; Deguchi S; Mori T; Tamura T; Toyokawa T; Muguruma K; Hirakawa K; Ohira M
    Int J Oncol; 2020 Jul; 57(1):171-182. PubMed ID: 32319601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.
    Ma J; Deng Y; Zhang M; Zhang Q
    Immunology; 2024 Nov; 173(3):536-551. PubMed ID: 39078223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD160 expression on CD8
    Liu S; Zhang W; Liu K; Wang Y
    Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A
    Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
    Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1
    Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
    Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
    Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded antigen-experienced CD160
    Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.
    Sakimura C; Tanaka H; Okuno T; Hiramatsu S; Muguruma K; Hirakawa K; Wanibuchi H; Ohira M
    J Surg Res; 2017 Jul; 215():74-82. PubMed ID: 28688665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution and maturation of tertiary lymphoid structures can predict clinical outcomes of patients with gastric adenocarcinoma.
    Sun H; Liu Y; Cheng W; Xiong R; Gu W; Zhang X; Wang X; Wang X; Tan C; Weng W; Zhang M; Ni S; Huang D; Xu M; Sheng W; Wang L
    Front Immunol; 2024; 15():1396808. PubMed ID: 39136032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study.
    Wang YQ; Chen WJ; Zhou W; Dong KQ; Zuo L; Xu D; Chen JX; Chen WJ; Li WY; Liu ZC; Jiang ZY; Tang YF; Qin YX; Wang LH; Pan XW; Cui XG
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Transcriptionally Distinct CXCL13
    Workel HH; Lubbers JM; Arnold R; Prins TM; van der Vlies P; de Lange K; Bosse T; van Gool IC; Eggink FA; Wouters MCA; Komdeur FL; van der Slikke EC; Creutzberg CL; Kol A; Plat A; Glaire M; Church DN; Nijman HW; de Bruyn M
    Cancer Immunol Res; 2019 May; 7(5):784-796. PubMed ID: 30872264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
    Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
    Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.